DK3365321T3 - Solabegron-zwitterion og anvendelser deraf - Google Patents
Solabegron-zwitterion og anvendelser deraf Download PDFInfo
- Publication number
- DK3365321T3 DK3365321T3 DK16858451.4T DK16858451T DK3365321T3 DK 3365321 T3 DK3365321 T3 DK 3365321T3 DK 16858451 T DK16858451 T DK 16858451T DK 3365321 T3 DK3365321 T3 DK 3365321T3
- Authority
- DK
- Denmark
- Prior art keywords
- solabegron
- zwitterion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245670P | 2015-10-23 | 2015-10-23 | |
US201562245656P | 2015-10-23 | 2015-10-23 | |
US201662345357P | 2016-06-03 | 2016-06-03 | |
US201662345574P | 2016-06-03 | 2016-06-03 | |
US201662345327P | 2016-06-03 | 2016-06-03 | |
PCT/US2016/058516 WO2017070689A2 (en) | 2015-10-23 | 2016-10-24 | Solabegron zwitterion and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3365321T3 true DK3365321T3 (da) | 2024-01-15 |
Family
ID=58557973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16858451.4T DK3365321T3 (da) | 2015-10-23 | 2016-10-24 | Solabegron-zwitterion og anvendelser deraf |
Country Status (12)
Country | Link |
---|---|
US (5) | US10065922B2 (da) |
EP (1) | EP3365321B1 (da) |
CN (2) | CN108290824B (da) |
CA (1) | CA3001850A1 (da) |
DK (1) | DK3365321T3 (da) |
ES (1) | ES2967863T3 (da) |
FI (1) | FI3365321T3 (da) |
HK (1) | HK1258038A1 (da) |
IL (2) | IL310527A (da) |
PL (1) | PL3365321T3 (da) |
PT (1) | PT3365321T (da) |
WO (1) | WO2017070689A2 (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
KR20170086659A (ko) | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법 |
PT3365321T (pt) | 2015-10-23 | 2024-01-12 | B3Ar Therapeutics Inc | Zwiterião de solabegron e suas utilizações |
CN111925294A (zh) * | 2020-07-06 | 2020-11-13 | 济南大学 | 一种托特罗定帕莫酸盐及其制备方法 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL124473C (da) | 1960-07-26 | |||
DE2965655D1 (en) | 1978-06-28 | 1983-07-21 | Beecham Group Plc | Secondary amines, their preparation, pharmaceutical compositions containing them and their use |
GB8519154D0 (en) | 1985-07-30 | 1985-09-04 | Ici Plc | Aromatic ethers |
DE3934436A1 (de) | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US5061727A (en) | 1990-05-04 | 1991-10-29 | American Cyanamid Company | Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles |
NO179246C (no) | 1991-11-20 | 1996-09-04 | Sankyo Co | Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav |
WO1995033724A1 (en) | 1994-06-09 | 1995-12-14 | Glaxo Group Limited | Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists |
US5677346A (en) | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
ATE239694T1 (de) | 1995-10-26 | 2003-05-15 | Mitsubishi Pharma Corp | Phenylethanolamin-verbindungen und ihre anwendung als beta3 agonisten, verfahren zu ihrer herstellung und zwischenprodukte ihrer herstellung |
US6123961A (en) | 1996-09-25 | 2000-09-26 | Bridge Pharma, Inc. | Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin |
GB9812709D0 (en) * | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
HU230454B1 (hu) | 1998-11-02 | 2016-07-28 | Alkermes Pharma Ireland Limited | Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény |
US20060240105A1 (en) | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
DE19856167C1 (de) | 1998-12-05 | 2000-05-04 | Vetter & Co Apotheker | Nadelschutzanordnung für Spritzen, Karpulen und dergleichen Injektionsinstrumente |
GB9929297D0 (en) | 1999-12-11 | 2000-02-02 | Glaxo Group Ltd | Process |
WO2001054728A1 (en) | 2000-01-28 | 2001-08-02 | Asahi Kasei Kabushiki Kaisha | NOVEL REMEDIES WITH THE USE OF β3 AGONIST |
US6444685B1 (en) | 2000-07-17 | 2002-09-03 | Wyeth | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
US6395762B1 (en) | 2000-07-17 | 2002-05-28 | American Home Products Corporation | Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
GB0102407D0 (en) * | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Process |
US7034053B2 (en) | 2001-01-31 | 2006-04-25 | Smithkline Beecham Corporation | Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors |
US7709677B2 (en) | 2001-01-31 | 2010-05-04 | Glaxosmithkline Llc | Process of preparing arylethanoldiamines |
KR20040047747A (ko) | 2001-03-13 | 2004-06-05 | 펜웨스트 파머슈티칼즈 컴파니 | 변시치료 제형 |
WO2003024483A1 (fr) | 2001-09-11 | 2003-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire |
TWI295669B (en) | 2002-10-30 | 2008-04-11 | Theravance Inc | Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds |
EP1424079A1 (en) | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
WO2005042021A2 (de) | 2003-11-03 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer |
DE10352132A1 (de) | 2003-11-04 | 2005-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten |
DE602004021847D1 (de) | 2003-11-27 | 2009-08-13 | Develogen Ag | Verfahren zur prävention und behandlung von diabetes mit neurturin |
MXPA06007173A (es) * | 2003-12-23 | 2006-08-23 | Astellas Pharma Inc | Derivados de aminoalcohol. |
WO2005065673A1 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Atomoxetine formulations |
EP1550447A1 (en) | 2004-01-02 | 2005-07-06 | Schering Aktiengesellschaft | Menstrual cycle control and improvement of conception rates in females |
WO2005077364A1 (ja) | 2004-02-18 | 2005-08-25 | Yamanouchi Pharmaceutical Co., Ltd. | ソリフェナシンの経皮投与製剤およびその経皮透過改善方法 |
EP1804778A1 (de) | 2004-10-18 | 2007-07-11 | Boehringer Ingelheim International GmbH | Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts |
LT1871347T (lt) | 2005-04-19 | 2016-11-10 | Novartis Ag | Farmacinė kompozicija |
EP1769792A1 (de) | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
ITMI20061581A1 (it) | 2006-08-04 | 2008-02-05 | Univ Bari | Ligandi del recettore beta-3 adrenergico e loro uso in terapia |
EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
WO2008121268A1 (en) | 2007-03-29 | 2008-10-09 | Merck & Co., Inc. | Combination therapy for the treatment-of lower urinary tract symptoms |
DK2064222T3 (da) | 2007-04-02 | 2014-07-21 | Theracos Inc | Benzyliske glycosid-derivater og fremgangsmåder til anvendelse deraf |
GB0714790D0 (en) | 2007-07-30 | 2007-09-12 | Jagotec Ag | Improvements in or relating to organic compounds |
PL2216021T3 (pl) | 2007-11-02 | 2013-03-29 | Astellas Pharma Inc | Kompozycja farmaceutyczna do leczenia zespołu pęcherza nadreaktywnego |
PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
EP2274296B1 (en) | 2008-04-04 | 2012-10-17 | Merck Sharp & Dohme Corp. | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
EP2181707A1 (en) | 2008-11-04 | 2010-05-05 | Astellas Ireland Co., Ltd. | Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent |
WO2010118291A2 (en) | 2009-04-10 | 2010-10-14 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
EP2427194B1 (en) | 2009-05-08 | 2014-10-08 | Merck Sharp & Dohme Corp. | Pyrrolidine-derived beta 3 adrenergic receptor agonists |
WO2010147830A2 (en) | 2009-06-15 | 2010-12-23 | Auspex Pharmaceuticals, Inc. | Aminothiazole modulators of beta-3-adrenoreceptor |
MX2012002366A (es) | 2009-08-27 | 2012-03-29 | Merck Sharp & Dohme | Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. |
US8354403B2 (en) | 2009-08-27 | 2013-01-15 | Merck Sharp & Dohme Corp. | Pyrrolidine derived beta 3 adrenergic receptor agonists |
AU2010303811B2 (en) | 2009-10-07 | 2013-01-24 | Merck Sharp & Dohme Corp. | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
MX2012006734A (es) | 2009-12-15 | 2012-07-03 | Metabolic Solutions Dev Co Llc | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas. |
AU2010340058A1 (en) | 2009-12-15 | 2012-06-21 | Metabolic Solutions Development Company, Llc | PPAR-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases |
AU2010331926B2 (en) | 2009-12-15 | 2014-03-27 | Cirius Therapeutics, Inc. | PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
US8748433B2 (en) | 2010-04-30 | 2014-06-10 | Merck Sharp & Dohme Corp. | β3 adrenergic receptor agonists |
AU2011285928B9 (en) * | 2010-08-03 | 2018-08-02 | B3Ar Therapeutics, Inc. | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
WO2016004056A1 (en) | 2014-07-03 | 2016-01-07 | Velicept Therapeutics, Inc. | Pharmaceutical combinations |
US9907767B2 (en) * | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
WO2012154770A1 (en) | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder |
JP2015509931A (ja) | 2012-02-09 | 2015-04-02 | アルセレックス,インコーポレイテッド | 医薬的な組み合わせ |
EP2891493A4 (en) | 2012-08-31 | 2016-05-18 | Astellas Pharma Inc | MEDICAL COMPOSITION ADMINISTERED ORALLY |
US20150306170A1 (en) | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
WO2014134005A2 (en) | 2013-02-26 | 2014-09-04 | Xenoport, Inc. | Method of making 1-(acyloxy)-alkyl carbamate compounds |
US10166183B2 (en) | 2014-02-07 | 2019-01-01 | Auspex Pharmaceuticals, Inc. | Pharmaceutical formulations |
KR20170086659A (ko) * | 2014-12-03 | 2017-07-26 | 벨리셉트 테라퓨틱스, 인크. | 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법 |
PT3365321T (pt) | 2015-10-23 | 2024-01-12 | B3Ar Therapeutics Inc | Zwiterião de solabegron e suas utilizações |
WO2017210700A1 (en) | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
EP3463312A4 (en) | 2016-06-03 | 2020-02-05 | Velicept Therapeutics, Inc. | DOSING SCHEMES FOR BETA-3-ADRENOCEPTORAGONISTS AND ANTIMUS CARINICAS FOR THE TREATMENT AND PREVENTION OF SYMPTOMS OF THE LOWER URINARY PATHWAYS AND OVERACTIVE BLADDER |
-
2016
- 2016-10-24 PT PT168584514T patent/PT3365321T/pt unknown
- 2016-10-24 ES ES16858451T patent/ES2967863T3/es active Active
- 2016-10-24 CN CN201680069478.7A patent/CN108290824B/zh active Active
- 2016-10-24 PL PL16858451.4T patent/PL3365321T3/pl unknown
- 2016-10-24 FI FIEP16858451.4T patent/FI3365321T3/fi active
- 2016-10-24 US US15/332,956 patent/US10065922B2/en active Active
- 2016-10-24 EP EP16858451.4A patent/EP3365321B1/en active Active
- 2016-10-24 WO PCT/US2016/058516 patent/WO2017070689A2/en active Application Filing
- 2016-10-24 IL IL310527A patent/IL310527A/en unknown
- 2016-10-24 IL IL258856A patent/IL258856B1/en unknown
- 2016-10-24 DK DK16858451.4T patent/DK3365321T3/da active
- 2016-10-24 CA CA3001850A patent/CA3001850A1/en active Pending
- 2016-10-24 CN CN202111549024.9A patent/CN114230477A/zh active Pending
-
2018
- 2018-06-26 US US16/018,945 patent/US10221126B2/en active Active
-
2019
- 2019-01-10 HK HK19100411.0A patent/HK1258038A1/zh unknown
- 2019-01-11 US US16/246,114 patent/US10844004B2/en active Active
-
2020
- 2020-10-22 US US17/077,446 patent/US11691944B2/en active Active
-
2023
- 2023-05-18 US US18/199,205 patent/US20240124391A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2017070689A2 (en) | 2017-04-27 |
WO2017070689A3 (en) | 2017-07-20 |
CN114230477A (zh) | 2022-03-25 |
EP3365321A2 (en) | 2018-08-29 |
US11691944B2 (en) | 2023-07-04 |
HK1258038A1 (zh) | 2019-11-01 |
CN108290824A (zh) | 2018-07-17 |
IL310527A (en) | 2024-03-01 |
IL258856B1 (en) | 2024-03-01 |
CN108290824B (zh) | 2022-03-11 |
FI3365321T3 (fi) | 2024-01-02 |
US20190185414A1 (en) | 2019-06-20 |
US10844004B2 (en) | 2020-11-24 |
CA3001850A1 (en) | 2017-04-27 |
PL3365321T3 (pl) | 2024-03-25 |
US10221126B2 (en) | 2019-03-05 |
US20170114005A1 (en) | 2017-04-27 |
US20180370902A1 (en) | 2018-12-27 |
EP3365321B1 (en) | 2023-12-13 |
ES2967863T3 (es) | 2024-05-06 |
EP3365321A4 (en) | 2019-06-05 |
IL258856A (en) | 2018-06-28 |
US10065922B2 (en) | 2018-09-04 |
US20240124391A1 (en) | 2024-04-18 |
US20210317073A1 (en) | 2021-10-14 |
PT3365321T (pt) | 2024-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
DK3368534T3 (da) | Valbenazin-ditosylat og polymorfer deraf | |
DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
DK3303379T3 (da) | Tigit-bindende midler og anvendelser deraf | |
DK3354282T3 (da) | Glycan-terapeutiske midler og relaterede fremgangsmåder deraf | |
DK3480213T3 (da) | Syntac-polypeptider og anvendelser deraf | |
DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
DK3099172T3 (da) | Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf | |
DK3015526T3 (da) | Hydrofluorolefinbaseret sammensætning og anvendelse deraf | |
DK3256598T3 (da) | Svampestammer og anvendelsesfremgangsmåder | |
DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
DK3236991T3 (da) | Fgf21-derivater og anvendelser deraf | |
DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
DK3256479T3 (da) | 4-substituerede benzoxaborolforbindelser og anvendelser deraf | |
MA49905A (fr) | Polyesteramines et polyesterquats | |
DK3386956T3 (da) | Fumagillolderivater og polymorfer deraf | |
DK3245219T3 (da) | Glypicanepitoper og anvendelser deraf | |
DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf |